B
BLC Clinical Research | Burlington, Canada
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Nalbuphine
DUPIXENT®
NOC-110
BI 1291583
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 4 total trials
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...
Active, not recruiting
Refractory or Unexplained Chronic Cough
Drug: NOC-110
Other: Placebo
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and...
Enrolling
Bronchiectasis
Drug: Placebo matching BI 1291583
Drug: BI 1291583
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
Enrolling
Refractory Chronic Cough
Drug: NAL ER
Drug: Placebo
Trial sponsors
N
T
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems